	US 11,732,308 B2
	Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
Ugur Sahin, Mainz (DE); Ozlem Tureci, Mainz (DE); and Daniel Maurus, Mainz (DE)
Assigned to Astellas Pharma Inc., Tokyo (JP); and TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBH, Mainz (DE)
Filed by Astellas Pharma Inc., Tokyo (JP); and TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ, Mainz (DE)
Filed on Dec. 23, 2020, as Appl. No. 17/133,107.
Application 17/133,107 is a division of application No. 15/565,306, granted, now 10,927,413, previously published as PCT/EP2016/058061, filed on Apr. 13, 2016.
Claims priority of application No. PCT/EP2015/058212 (WO), filed on Apr. 15, 2015.
Prior Publication US 2021/0324472 A1, Oct. 21, 2021
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6883 (2018.01); A61K 47/68 (2017.01); A61K 39/395 (2006.01)

CPC C12Q 1/6886 (2013.01) [C12Q 1/6883 (2013.01); A61K 39/39558 (2013.01); A61K 47/6801 (2017.08); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01)]

31 Claims

1. A method of treating a human cancer patient having a CLDN18.2-positive tumor, said method comprising

a. determining or having determined a genotype for at least one single-nucleotide polymorphism in a sample obtained from the cancer patient, the at least one single-nucleotide polymorphism including FCGR2A rs1801274;

b. identifying the cancer patient as a likely responder to treatment with an anti-CLDN18.2 antibody based on the patient having a heterozygous FCGR2A rs1801274 [CT] genotype; and

c. administering the anti-CLDN18.2 antibody to the human cancer patient.